Assessment of hepatitis B vaccine-induced seroprotection among children 5-10 years old in Ulaanbaatar, Mongolia.

Hepatitis B virus infection is a serious public health problem. Mongolia is one of the countries with the highest rates of hepatitis B virus infection in the world. The routine immunization with the hepatitis B vaccine began nationwide in 1991. The purpose of this study was to determine the persistence of seroprotection (anti-HBs >or= 10 mlU/mL) in children 5-10 years old that were immunized with the hepatitis B vaccine as infants. In total, 438 children were selected from six health facilities in Ulaanbaatar through a multistage random sampling method. Vaccination information was confirmed by checking the vaccination records kept in the health facilities. A blood sample was obtained from each child for anti-HBs, HBsAg and anti-HBc. Of 438 children, five (1.1%) were HBsAg positive and 58 (13.2%) were anti-HBc positive. Sixty infected children were excluded and a total of 378 (86.3%) sera were evaluated. The seroprotective antibodies were detected in only one-fourth of the children at the age of ten. Titres of anti-HBs decreased significantly with age (Linear regression p = 0.01). This decrease is primarily due to the rapid decrease in children living in ger areas (p < 0.001) compared to children living in apartment areas (p = 0.152). On the other hand, children living with higher socio-economic status had more exposure to blood-borne pathogens, probably due to inappropriate health-seeking behaviors.

[1]  T. Nishizawa,et al.  Infection with hepatitis A, B, C, and delta viruses among patients with acute hepatitis in Mongolia , 2006, Journal of medical virology.

[2]  S. Wiersma,et al.  Progress in the control of hepatitis B infection in the Western Pacific Region. , 2006, Vaccine.

[3]  Y. Hutin,et al.  Rapid assessment of injection practices in Mongolia. , 2004, American journal of infection control.

[4]  P. Nymadawa,et al.  Comparison of hepatitis B vaccine coverage and effectiveness among urban and rural Mongolian 2-year-olds. , 2002, Preventive medicine.

[5]  European Consensus Group on Hepatitis B Immunity Are booster immunisations needed for lifelong hepatitis B immunity? , 2000, The Lancet.

[6]  T. Nishizawa,et al.  High Prevalence of Antibodies to Hepatitis A and E Viruses and Viremia of Hepatitis B, C, and D Viruses among Apparently Healthy Populations in Mongolia , 2004, Clinical Diagnostic Laboratory Immunology.

[7]  M. On,et al.  Long-term immunogenicity and efficacy of a recombinant hepatitis B vaccine in Egyptian children. , 1999, Eastern Mediterranean health journal = La revue de sante de la Mediterranee orientale = al-Majallah al-sihhiyah li-sharq al-mutawassit.

[8]  Hong-jian Yan,et al.  Hepatitis B revaccination in healthy non-responder Chinese children: five-year follow-up of immune response and immunologic memory. , 2006, Vaccine.

[9]  Sheng-Nan Lu,et al.  Hepatitis B virus infection in adolescents in a rural township--15 years subsequent to mass hepatitis B vaccination in Taiwan. , 2006, Vaccine.

[10]  T. Altantsetseg,et al.  Emerging Infectious Diseases in Mongolia , 2003, Emerging infectious diseases.

[11]  M. Chang,et al.  Long-term efficacy of recombinant hepatitis B vaccine and risk of natural infection in infants born to mothers with hepatitis B e antigen. , 1995, The Journal of pediatrics.

[12]  B. McMahon,et al.  Long-term efficacy of hepatitis B vaccine, booster policy, and impact of hepatitis B virus mutants. , 2005, Vaccine.

[13]  A. Zanetti,et al.  Long-term immunogenicity of hepatitis B vaccination and policy for booster: an Italian multicentre study , 2005, The Lancet.

[14]  M. Miyoshi,et al.  Non-polio enterovirus isolation among families in Ulaanbaatar and Tov province, Mongolia: prevalence, intrafamilial spread, and risk factors for infection , 2005, Epidemiology and Infection.

[15]  James S Edstam,et al.  Exposure of hepatitis B vaccine to freezing temperatures during transport to rural health centers in Mongolia. , 2004, Preventive medicine.

[16]  O. N. Mohamed,et al.  Long-term immunogenicity and efficacy of a recombinant hepatitis B vaccine in Egyptian children. , 1999, Eastern Mediterranean health journal = La revue de sante de la Mediterranee orientale = al-Majallah al-sihhiyah li-sharq al-mutawassit.

[17]  John E. Bennett,et al.  Principles and practice of infectious diseases. Vols 1 and 2. , 1979 .

[18]  M. Yuen,et al.  Twelve‐year follow‐up of a prospective randomized trial of hepatitis b recombinant DNA yeast vaccine versus plasma‐derived vaccine without booster doses in children , 1999, Hepatology.

[19]  M. Yuen,et al.  18-year follow-up study of a prospective randomized trial of hepatitis B vaccinations without booster doses in children. , 2004, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[20]  P. Chou,et al.  Comparison of hepatitis B virus and hepatitis C virus prevalence and risk factors in a community-based study. , 2002, The American journal of tropical medicine and hygiene.

[21]  M. Kane Global status of hepatitis B immunisation , 1996, The Lancet.

[22]  J M Lepkowski,et al.  Socioeconomic factors, health behaviors, and mortality: results from a nationally representative prospective study of US adults. , 1998, JAMA.

[23]  S. Twu,et al.  Waning immunity to plasma‐derived hepatitis B vaccine and the need for boosters 15 years after neonatal vaccination , 2004, Hepatology.

[24]  H. Margolis,et al.  Antibody Levels and Protection after Hepatitis B Vaccination: Results of a 15-Year Follow-up , 2005, Annals of Internal Medicine.

[25]  B. McMahon,et al.  Duration of Hepatitis B Immunity in Low Risk Children Receiving Hepatitis B Vaccinations From Birth , 2004, The Pediatric infectious disease journal.

[26]  A MarioCalvo,et al.  Antibody levels and protection after hepatitis B vaccination: Results of a 15-year follow-up , 2005 .